Tocilizumab versus anakinra in COVID-19: results from propensity score matching

BackgroundTocilizumab and anakinra are anti-interleukin drugs to treat severe coronavirus disease 2019 (COVID-19) refractory to corticosteroids. However, no studies compared the efficacy of tocilizumab versus anakinra to guide the choice of the therapy in clinical practice. We aimed to compare the o...

Descripció completa

Dades bibliogràfiques

Autors principals:	Robin Arcani, Florian Correard, Pierre Suchon, Gilles Kaplanski, Rodolphe Jean, Raphael Cauchois, Marine Leprince, Vincent Arcani, Julie Seguier, Benjamin De Sainte Marie, Baptiste Andre, Marie Koubi, Pascal Rossi, Stéphane Gayet, Nirvina Gobin, Victoria Garrido, Joris Weiland, Elisabeth Jouve, Anne-Laure Couderc, Patrick Villani, Aurélie Daumas
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2023-05-01
Col·lecció:	Frontiers in Immunology
Matèries:	anakinra tocilizumab anti-interleukin drugs COVID-19 mortality SARS-CoV-2
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1185716/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!